30
Participants
Start Date
August 9, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Axicabtagene Ciloleucel
Administered intravenously
Cyclophosphamide
Administered intravenously
Fludarabine
Administered intravenously
Dexamethasone
Administered orally or intravenously
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
University of Virginia Health System, Charlottesville
Virginia Commonwealth University, Richmond
Virginia Oncology Associates, Norfolk
Prisma Health - Upstate, Greenville
Tennessee Oncology, PLLC, Nashville
Henry-Joyce Cancer Clinic, Nashville
Oncology Hematology Care Clinical Trials, LLC, Cincinnati
Barbara Ann Karmanos Cancer Institute, Detroit
Methodist Healthcare System of San Antonio, San Antonio
Colorado Blood Cancer Institute, Denver
Intermountain Healthcare, Murray
Huntsman Cancer Institute, University of Utah, Salt Lake City
UCLA, Los Angeles
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Kite, A Gilead Company
INDUSTRY